TNFRSF17 and Miyoshi myopathy: These engineered NK cells were designed based on the premises that BCMA is over-expressed on the surface of malignant plasma cells and anti-BCMA CAR enabled the NK-92 cells to recognize and kill MM cells in pre-clinical models.